The impact of astragaloside Ⅳ on the experimentally atherosclerotic formation in ApoE-deficient mice
10.3760/cma.j.issn.1008-1372.2017.12.017
- VernacularTitle:黄芪甲苷对ApoE-/-小鼠动脉粥样硬化的影响
- Author:
Xiaolin LI
1
;
Weining CHENG
;
Longhu HUANG
;
Jing ZHU
;
Dazhu LI
Author Information
1. 华中科技大学同济医学院附属武汉市中心医院新洲院区心内科
- Keywords:
Astragalus membranaceus;
Apolipoproteins E;
Atherosclerosis/ZD
- From:
Journal of Chinese Physician
2017;19(12):1817-1819,1823
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the impacts of astragalosideⅣ( AST-Ⅳ) on the experimentally atherosclerotic formation in ApoE-deficient mice. Methods ApoE-deficient mice were randomly divided into AST-Ⅳ and control groups, both groups were fed with high-fat diet, and were killed after 12 weeks of treatment. The plaque areas were measured; the percentage of CD4 +CD25 + T cells were determined by flow cytometry;the levels of supernatant cytokine such as interferon ( IFN )-γ, interleukin ( IL )-10 and transforming growth factor-β (TGF-β) were measured by enzyme-linked immunosorbent assay (ELISA). Results The plaque area of AST-Ⅳ group was ( 815. 78 ± 165. 43 )μm2 , which was smaller than that in control group of (2152. 13 ± 525. 47)μm2. The percentage of CD4 +CD25 +Treg accounted for (9. 86 ± 1. 78)％ of CD4 + cells, which was higher than that in control group (2. 52 ± 1. 43) ％. Compared to con-trol group, the supernatant levels of IL-10 and TGF-βwere significantly higher, and IFN-γwas significantly lower in AST-Ⅳ group (P<0. 05). Conclusions By influencing the regulatory T cell-mediated immune tolerance, AST-Ⅳ might inhibit atherosclerosis in mice.
